Fig. 1: Cav-1 increases CSC subpopulation.
From: The paracrine induction of prostate cancer progression by caveolin-1
a Prostate sphere formation of LNCaP (Vc vs. CavOE) and Du145 (Vc vs. shCav1) was determined after 14 days cultured in ultralow attachment plate. Number of spheres was counted and normalized with control cells (e.g., LNCaP Vc or Du145 shCav1), respectively. Data were shown as mean ± SD (n > 10), ***P < 0.001. Scale bar = 50 μm. b CSC subpopulation was determined by Flow cytometry based on CD24low and CD44high population. c The gene expression of Yamanaka factors was measured by qRT-PCR. Data were shown as mean ± SD (n > 10), *P < 0.5, **P < 0.01, ***P < 0.001. e In vivo tumorigenicity of Du145 Vc vs. shCav1 cells was measured at Day 35 and Day 49 post injection. d A serial dilution of Du145 Vc or shCav1 cells was subcutaneously injected into immune-deficient mice. Tumor incidence was analyzed after 35 days and 49 days of injection. e Clinical correlation of Cav-1 mRNA expression in PCa patients from two cohorts was obtained by using Oncomine Database. Cav-1 mRNA expression was compared between primary site and metastasis site of tumor
